By PPN News Staff
The FDA released draft guidance for 503B compounding facilities.
The 48-page document describes the FDA’s draft policies for 503B facilities that compound human drugs and are registered as an outsourcing facility: compounding facilities that are permitted under law to compound and distribute certain compounded drugs without receiving patient-specific prescriptions.
The guidance is intended to help facilities stay in compliance with Current Good Manufacturing Practice